Haubitz M, Brunkhorst R, Schellong S, Gobel U, Schurek HJ,
Koch KM
ANCA-associated vasculitis and renal involvement: preliminary
results of a prospective randomized study comparing daily oral versus
monthly I.V. cyclophosphamide application
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Nov) 6:922 1995
I.V. cyclophosphamide is less toxic than P.O. administration, yet its
efficacy in ANCA + renal vasculitis is unclear. Data from 37 patients
randomized to monthly I.V. (750 mg/m2 BSA) or daily P.O. (2 mg/kd/d) therapy
were compared. Remission and relapse rates were not different between the
groups. Bone marrow toxicity was significantly decreased in the I.V.
group.
(Leehey)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
Proteinuria/Hematuria :
Vasculitis (Wegener's PAN, etc.)